Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
The therapy also delivered significant improvements in key liver enzyme markers
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Former Wavemaker executive to lead media strategy and digital transformation agenda
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
